Ivana Magovčević-Liebisch, Vigil Neuroscience CEO

Vig­il Neu­ro­science hits Wall Street with two ex-Am­gen TREM2 ag­o­nists

Big Phar­ma large­ly aban­doned neu­ro­science over the last sev­er­al years — but the folks at Vig­il Neu­ro­science be­lieve a re­nais­sance is around the cor­ner, and ap­par­ent­ly, so do in­vestors.

The Cam­bridge, MA-based start­up closed a $98 mil­lion IPO on Tues­day, pric­ing 7 mil­lion shares at $14, just be­low an ex­pect­ed $15 to $17 range. Most of that is go­ing to­ward VGL101, an ex-Am­gen TREM2 ag­o­nist in Phase I for a rare neu­rode­gen­er­a­tive dis­ease.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters